| Filed On | Filing |
|---|---|
| 10 Nov 2026 | SCHEDULE 13G |
| 04 Nov 2026 | 10-Q |
| 04 Nov 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
— Maintained Full Year 2026 ORLADEYO revenue guidance of $625 to $645 million and increased total revenue guidance to $715 million to $730 million — |
| 02 Sep 2026 |
Form 4: Stonehouse Jon P, Director
Received 644 shares as a grant or award ($6.25K) |
| 02 Sep 2026 |
Form 4: Milne Jill C., Director
Received 1,288 shares as a grant or award ($12.5K) |
| 02 Sep 2026 |
Form 4: Milano Vincent, Director
Received 1,159 shares as a grant or award ($11.2K) |
| 02 Sep 2026 |
Form 4: McKee Amy E, Director
Received 644 shares as a grant or award ($6.25K) |
| 02 Sep 2026 |
Form 4: Frank Steven, Director
Received 1,288 shares as a grant or award ($12.5K) |
| 14 Aug 2026 | SCHEDULE 13G/A |
| 07 Aug 2026 | SCHEDULE 13G |
| 05 Aug 2026 | FORM S-8 |
| 05 Aug 2026 | 10-Q |
| 05 Aug 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
— Maintained Full Year 2026 ORLADEYO revenue guidance of $625 to $645 million and increased total revenue guidance to $690 million to $715 million — |
| 04 Aug 2026 |
8-K/A: Costs Associated with Exit or Disposal Activities
On June 29, 2026, the Company announced its plan to discontinue the Company’s internal discovery programs and close its Discovery Center of Excellence facility in Birmingham, Alabama (the “Plan”) as part of the Company’s ongoing strategi... |
| 29 Jun 2026 |
8-K: Costs Associated with Exit or Disposal Activities; Regulation FD Disclosure
BioCryst Sharpens Scientific Focus on External Innovation with Wind Down of Internal Discovery Programs and Closure of Birmingham Research Facility |
| 15 Jun 2026 |
Form 4: Milne Jill C., Director
Received 15,294 shares as a grant or award · Granted 33,540 Automatic Stock Option Grant |
| 15 Jun 2026 |
Form 4: Galson Steven K, Director
Received 15,294 shares as a grant or award · Granted 33,540 Automatic Stock Option Grant |
| 15 Jun 2026 |
Form 4: Levin Alan G, Director
Received 15,294 shares as a grant or award · Granted 33,540 Automatic Stock Option Grant |
| 15 Jun 2026 |
Form 4: Frank Steven, Director
Received 15,294 shares as a grant or award · Granted 33,540 Automatic Stock Option Grant |
| 15 Jun 2026 |
Form 4: Sanders Machelle, Director
Received 15,294 shares as a grant or award · Granted 33,540 Automatic Stock Option Grant |
Loading...